Increasing Etoposide Sensitivity in Brain Tumor Cells
Author Information
Author(s): T Asanol, LA Zwelling, T An, A McWatters, CE Herzog, J Mayes, SM Loughlin, ES Kleinerman
Primary Institution: The University of Texas M.D. Anderson Cancer Center
Hypothesis
Can transfecting a Drosophila topoisomerase II gene into HBT20 human brain tumor cells increase their sensitivity to etoposide?
Conclusion
Transfection of the Drosophila topoisomerase II gene into human brain tumor cells increased their sensitivity to etoposide, but this effect was time-limited.
Supporting Evidence
- HBT20 cells are intrinsically resistant to etoposide with an IC50 of 13 µM.
- Transfection of the Drosophila topoisomerase II gene resulted in a 3-fold increase in sensitivity to etoposide after 24 hours of dexamethasone stimulation.
- Endogenous human topoisomerase II levels decreased after dexamethasone exposure.
Takeaway
Scientists tried to make brain cancer cells more sensitive to a drug called etoposide by adding a gene from fruit flies. It worked for a little while, but then stopped working after some time.
Methodology
The study involved transfecting a Drosophila topoisomerase II gene into HBT20 cells and measuring their sensitivity to etoposide after dexamethasone treatment.
Limitations
The increased sensitivity to etoposide was only temporary and diminished after 24 hours of dexamethasone treatment.
Participant Demographics
The study used a human brain tumor cell line (HBT20) established from a patient who had not received prior chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website